Amgen AMGN Repatha — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's repatha — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's repatha — total revenues?
- Amgen (AMGN) reported repatha — total revenues of $876M in Q1 2026.
- How has Amgen's repatha — total revenues changed year-over-year?
- Amgen's repatha — total revenues increased by 33.5% year-over-year, from $656M to $876M.
- What is the long-term trend for Amgen's repatha — total revenues?
- Over 3 years (2021 to 2024), Amgen's repatha — total revenues has grown at a 25.8% compound annual growth rate (CAGR), from $1.12B to $2.22B.
- What does repatha — total revenues mean?
- The total net revenue generated by the specific therapeutic product after all commercial adjustments.
- How do you interpret repatha — total revenues?
- An increase reflects successful market penetration and sustained therapeutic adoption, whereas a decrease may signal patent cliffs, generic competition, or loss of market share.
- How does repatha — total revenues compare across companies?
- Comparable to net product sales reported by peer biotech companies for their key commercialized assets.